FDA Approves OXYMORPHONE HYDROCHLORIDE — Amneal Pharmaceuticals of New York LLC

# FDA Approves Amneal Pharmaceuticals' Generic Oxymorphone Hydrochloride Amneal Pharmaceuticals of New York LLC received FDA approval for its generic oxymorphone hydrochloride oral formulation, positioning the company to compete in the pain management market as patent protections on the branded medication expire. The approval enables Amneal to capture market share in the opioid analgesic segment, where generic alternatives typically command significant pricing advantages over branded competitors.